These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 18332662)

  • 21. Tardive dyskinesia: eliminated, forgotten, or overshadowed?
    Remington G
    Curr Opin Psychiatry; 2007 Mar; 20(2):131-7. PubMed ID: 17278910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics.
    Rosenheck RA
    Br J Psychiatry; 2007 Sep; 191():238-45. PubMed ID: 17766765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tardive dyskinesia and impaired glucose tolerance.
    Chong SA; Mythily ; Lum A; Huak CY; Kane J
    Hum Psychopharmacol; 2002 Aug; 17(6):305-7. PubMed ID: 12404676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Shanghai 800: prevalence of tardive dyskinesia in a Chinese psychiatric hospital.
    Ko GN; Zhang LD; Yan WW; Zhang MD; Buchner D; Xia ZY; Wyatt RJ; Jeste DV
    Am J Psychiatry; 1989 Mar; 146(3):387-9. PubMed ID: 2563929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of olanzapine on tardive dyskinetic symptoms in a state hospital population.
    Brar JS; Parepally H; Chalasani L; Gopalani A; Appel N; Chengappa KN
    Ann Clin Psychiatry; 2008; 20(3):139-44. PubMed ID: 18633740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
    Margolese HC; Chouinard G; Kolivakis TT; Beauclair L; Miller R; Annable L
    Can J Psychiatry; 2005 Oct; 50(11):703-14. PubMed ID: 16363464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.
    Carbon M; Hsieh CH; Kane JM; Correll CU
    J Clin Psychiatry; 2017 Mar; 78(3):e264-e278. PubMed ID: 28146614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
    Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical and epidemiologic aspects of tardive dyskinesia.
    Baldessarini RJ
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):8-13. PubMed ID: 2858483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risperidone implicated in the onset of tardive dyskinesia in a young woman.
    Kumar S; Malone DM
    Postgrad Med J; 2000 May; 76(895):316-7. PubMed ID: 10775299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does clozapine cause tardive dyskinesia?
    Kane JM; Woerner MG; Pollack S; Safferman AZ; Lieberman JA
    J Clin Psychiatry; 1993 Sep; 54(9):327-30. PubMed ID: 8104929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The treatment of tardive dyskinesia and tardive dystonia.
    Simpson GM
    J Clin Psychiatry; 2000; 61 Suppl 4():39-44. PubMed ID: 10739330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
    Tenback DE; van Harten PN; Slooff CJ; van Os J
    Am J Psychiatry; 2006 Aug; 163(8):1438-40. PubMed ID: 16877660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vulnerability to tardive dyskinesia.
    Wolf ME; DeWolfe AS; Ryan JJ; Lips O; Mosnaim AD
    J Clin Psychiatry; 1985 Sep; 46(9):367-8. PubMed ID: 2863257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.
    Keck PE; McElroy SL; Strakowski SM; Soutullo CA
    J Clin Psychiatry; 2000; 61 Suppl 4():33-8. PubMed ID: 10739329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review.
    Pardis P; Remington G; Panda R; Lemez M; Agid O
    J Psychopharmacol; 2019 Oct; 33(10):1187-1198. PubMed ID: 31347436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Historical perspective on movement disorders.
    Friedman JH
    J Clin Psychiatry; 2004; 65 Suppl 9():3-8. PubMed ID: 15189105
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis.
    O'Brien A
    Int J Geriatr Psychiatry; 2016 Jul; 31(7):683-93. PubMed ID: 26679687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.
    Gebhardt S; Härtling F; Hanke M; Mittendorf M; Theisen FM; Wolf-Ostermann K; Grant P; Martin M; Fleischhaker C; Schulz E; Remschmidt H
    Eur Child Adolesc Psychiatry; 2006 Oct; 15(7):371-82. PubMed ID: 16648965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.